Renowned stock market guru and CNBC host, Jim Cramer, weighed in on the potential value of GLP-1 drugs, commonly used to treat diabetes and obesity, as well as the companies producing them, such as Eli Lilly and Novo Nordisk. Cramer stated that these drugs could be extremely valuable with a significant impact on the pharmaceutical market.
He specifically emphasized the potential cost-saving benefits for insurance companies in the long run. Cramer argued that it would be more cost-effective for insurance companies to invest in new weight-loss drugs rather than dealing with the costly health complications that can arise from morbid obesity.
Cramer hailed these drugs as “revolutionary,” citing recent data from Novo Nordisk showing that their drug Wegovy reduced the risk of serious cardiovascular complications in patients with obesity and heart disease by 20%. Despite concerns from some analysts about insurance companies paying for the drugs, Cramer remained optimistic. He believes that there are many patient groups who could vastly benefit from these medications, leading to potential coverage by insurers in order to prevent future illnesses.
Cramer also pointed out various medical conditions, such as type two diabetes and treatment-resistant high blood pressure, where these drugs could have a significant impact in preventing further complications. He emphasized that there are more uses for these drugs that are just beginning to be explored, such as their potential in treating alcoholism, which could lead to a range of health problems.
In light of these developments, Cramer’s outlook was positive, as he predicted a potential rise in stock prices for Eli Lilly and Novo Nordisk once these “miracle” drugs are mass-produced and made available in pill form.
For further stock investment insights and updates on the market, interested individuals can sign up for the CNBC Investing Club to keep up with Jim Cramer’s latest moves. It’s important to note, however, that the CNBC Investing Club Charitable Trust holds shares of Eli Lilly.
For inquiries or to delve deeper into Cramer’s world, individuals can connect with him through various social media channels or contact his team via email. Jim Cramer remains optimistic about the future prospects of the pharmaceutical companies and their weight loss drugs, highlighting the potential transformative impact these drugs could have on the market and patient outcomes.
I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.
